Clozapine-treated subjects with treatment-resistant schizophrenia: a systematic review of experimental and observational studies

被引:15
作者
Brambilla, P
Barale, F
Caverzasi, E
Tognoni, G
Barbui, C [1 ]
机构
[1] Univ Verona, Dept Med & Publ Hlth, Sect Psychiat, Osped Policlin, I-37134 Verona, Italy
[2] Univ Pavia, Sch Med, IRCCS S Matteo, Dept Psychiat, I-27100 Pavia, Italy
[3] Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy
关键词
clozapine; observational studies; prospective studies; randomized controlled trials; treatment-resistant schizophrenia; retrospective studies;
D O I
10.1097/00004850-200207000-00006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Randomized clinical trials have limitations because they focus on small samples of highly selected patients. Observational studies, which follow large cohorts of typical patients receiving pharmacological treatments, should overcome some of these trial limitations and provide information that cannot be generated with clinical trials. The present study aimed to compare experimental and observational studies of clozapine-treated subjects with treatment-resistant schizophrenia. A systematic review of experimental and observational studies evaluating clozapine-treated subjects in treatment-resistant schizophrenia was carried out. We identified 50 studies that met the inclusion criteria. Less than one-third of clinical trials enrolled more than 50 patients compared to 44% of prospective and nearly 90% of retrospective studies. In addition, 78% of prospective and 89% of retrospective observational studies lasted more than 12 weeks, while the majority of trials lasted less than 8 weeks. Most clinical trials defined treatment-resistant schizophrenia according to Kane's criteria, while the majority of observational studies adopted implicit criteria. In comparison with clinical trials, observational studies provided a higher weighted mean rate of clozapine-responders and a lower weighted mean rate of clozapine-dropouts. This literature survey suggests that the role of observational studies in the evaluation of medicines should be reconsidered. A new generation of observational studies should be developed to provide evidence on patient outcome in typical settings and under real-world circumstances, and on variables which may affect outcome. Int Clin Psychopharmacol 17:189-195 (C) 2002 Lippincott Williams Wilkins.
引用
收藏
页码:189 / 195
页数:7
相关论文
共 60 条
[1]   THE SAFETY AND EFFICACY OF CLOZAPINE IN SEVERE TREATMENT-RESISTANT SCHIZOPHRENIC-PATIENTS IN THE UK [J].
ADAMS, CE ;
BARNES, TRE ;
ESSALI, MA ;
HIRSCH, SR ;
MACKAY, AVP ;
CORRIGAN, FM ;
CUTTING, JC ;
EKDAWI, MY ;
MCKENNA, PJ ;
MILLN, PTS ;
PARKER, AL ;
LADER, M ;
BROWNSEY, RL .
BRITISH JOURNAL OF PSYCHIATRY, 1993, 163 :150-154
[2]   Effectiveness of clozapine in hospitalised people with chronic neuroleptic-resistant schizophrenia [J].
Avnon, M ;
Rabinowitz, J .
BRITISH JOURNAL OF PSYCHIATRY, 1995, 167 :760-764
[3]   A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia [J].
Azorin, JM ;
Spiegel, R ;
Remington, G ;
Vanelle, JM ;
Péré, JJ ;
Giguere, M ;
Bourdeix, I .
AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (08) :1305-1313
[4]   High-quality clinical databases: breaking down barriers [J].
Black, N .
LANCET, 1999, 353 (9160) :1205-1206
[5]   Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study [J].
Bondolfi, G ;
Dufour, H ;
Patris, M ;
May, JP ;
Billeter, U ;
Eap, CB ;
Baumann, P .
AMERICAN JOURNAL OF PSYCHIATRY, 1998, 155 (04) :499-504
[6]  
BORISON RL, 1988, PSYCHOPHARMACOL BULL, V24, P260
[7]  
BRAMBILLA P, 2000, ACTA PSYCHIAT SCAN S, V102, P72
[8]  
BREIER A, 1993, HOSP COMMUNITY PSYCH, V44, P1145
[9]  
BREIER A, 1994, AM J PSYCHIAT, V151, P20
[10]  
Breier AF, 1999, AM J PSYCHIAT, V156, P294